Ipsen SA

Ipsen initiates a share buy-back program to cover its free employee share-allocation plan

02 Jun 2024 22:00:00 By Nasdaq GlobeNewswire

Ipsen announces the launch of an employee shareholding plan

30 May 2024 09:15:00 By Nasdaq GlobeNewswire

Annual General Meeting of Ipsen S.A. held on 28 May 2024

28 May 2024 09:00:00 By Nasdaq GlobeNewswire

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024

27 May 2024 22:00:00 By Nasdaq GlobeNewswire

Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting

07 May 2024 05:55:54 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06 May 2024 09:00:00 By Nasdaq GlobeNewswire

Ipsen appoints Keira Driansky as EVP, President of North America

01 May 2024 22:30:00 By Nasdaq GlobeNewswire

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

23 Apr 2024 22:00:00 By Nasdaq GlobeNewswire

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

21 Apr 2024 22:00:00 By Nasdaq GlobeNewswire

Ipsen publishes its 2023 Universal Registration Document

17 Apr 2024 09:00:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

08 Apr 2024 09:00:00 By Nasdaq GlobeNewswire

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

01 Apr 2024 22:00:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

07 Mar 2024 09:00:00 By Nasdaq GlobeNewswire

Ipsen S.A. publishes its 2023 Consolidated Financial Statements

15 Feb 2024 01:00:45 By Nasdaq GlobeNewswire

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  

13 Feb 2024 13:08:23 By Nasdaq GlobeNewswire

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

07 Feb 2024 21:58:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06 Feb 2024 09:00:00 By Nasdaq GlobeNewswire

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

22 Jan 2024 14:00:00 By Nasdaq GlobeNewswire

Ipsen – Half year statement – 2023 12 31

08 Jan 2024 09:00:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

05 Jan 2024 09:00:00 By Nasdaq GlobeNewswire